Associated Papers
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.
Sposito M et al.
Scientific Reports, 2025
41053251 (PubMed )
Supplement: 41598_2025_18662_MOESM1_ESM.docx
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma.
Fabregat-Franco C et al.
Esmo Open, 2025
40359709 (PubMed )
Supplement: mmc2.docx
Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis.
Wen S et al.
Nature Genetics, 2025
39948438 (PubMed )
Supplement: 41588_2025_2085_MOESM4_ESM.xlsx › ST22
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
Comprehensive analysis of the functional impact of single nucleotide variants of human CHEK2.
McCarthy-Leo CE et al.
Plos Genetics, 2024
39146382 (PubMed )
Supplement: pgen.1011375.s008.xlsx › All_SNVs_Data
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis.
Storandt MH et al.
Cancers, 2023
37509234 (PubMed )
Supplement: cancers-15-03570-s001.zip › cancers-2473295-supplementary.pdf
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I et al.
Nature, 2021
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Select a paper to view details